RAY1225
Phase 3Small molecule
RAY1225 is one of 57 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.
2
Indications
10
Total Trials
7
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 3
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes3 trials
Function2 trials
Atorvastatin1 trial
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RAY1225. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details